Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (135 reviews)

For research use only. Not for use in humans.

Catalog No.S2807

135 publications

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 135 publications

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )
Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )
Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )
ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )
Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )
Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MoDHT4lv[XOnIFHzd4F6				NIj3XWtKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{KHSjZ3fl[EBDNVKjZjDWOlAxTSCvdYThcpQh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDj[YxteyClbz3lfJBz\XO\|aX7nJGNFSzN5IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGKrb4Tpcplt[XSnZD3NSWsheHKxdHXpckBxcG:\|cHjvdplt[XSrb36gZpkhSWyyaHHTZ5Jm\W5iYYPzZZkhf2m2aDDJR\|UxKG:oIECuNFAxPyEQvF2=	NWHkfpBSOjR7MEC2O\|M>
SK-MEL-28	M4rDcmtqdmG\|ZTDBd5NigQ>?		M2TjelEhcA>?		MXHJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	M1fXSFI1QTByNkez
HepG2	MmSyT4lv[XOnIFHzd4F6				NIm5UZpKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1?	MVWyOFkxODZ5Mx?=
COLO205	NF7BbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zZfGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR\|UxKG:oIECuNFA4KM7:TR?=	NIfMV2QzPDlyME[3Ny=>
HepG2	NYf0OpI3TnWwY4Tpc44hSXO\|YYm=		MorvOFUhdWmw	MoDFSG1UVw>?	MVTJcohq[mm2aX;uJI9nKEGua{WgbY4hXEeILXLleIEue3SrbYXsZZRm\CCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBUdWGmMjDwbI9{eGixconsZZRqd25idILlZZRm\CCob4KgOFUhdWmwczDwdolweiC2bzDUS2Yu[mW2YTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjC2NEBucW6\|IHL5JI9lgXO\|ZYmgZoxwfCC\|Y3HucoVzKGGwYXz5d4l{KHerdHigTWM2OCCxZjCzMlch\|ryP	NEjMT44zPDlyME[3Ny=>
HFF	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r0SFExKM7:TR?=	Mme5O\|IhcA>?	MYLEUXNQ	MVPJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gTGZHKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSi2UYX[ge4l1cCCLQ{WwJI9nKDNizszN	NV;RSmdwOjN6NESwN\|g>
SK-MEL-28	NUHlV\|ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPDNVAh\|ryP	Ml\RO\|IhcA>?	MVLEUXNQ	MoHDTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKFONLV3FUE0zQCClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODR\|IN88US=>	NEjSXIEzOzh2NECzPC=>
A375P-F11	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;Te5gyOCEQvF2=	NUHGO2NbPzJiaB?=	NHvOPZZFVVOR	M1W0WGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0>	MWqyN\|g1PDB\|OB?=
MALME-3M	NFzGd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTUNVAh\|ryP	M3ztcFczKGh?	M{K5fWROW09?	MXfJR\|UxRTFibl2=	NHTLRYMzOzh2NECzPC=>
UACC-62	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj5WYEyOCEQvF2=	M1PUXlczKGh?	NF;q[GdFVVOR	NHLucYxKSzVyPUGgcm0>	NFTvSlEzOzh2NECzPC=>
C32TG	NGSxbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXmxNEDPxE1?	MnrtO\|IhcA>?	Mk\JSG1UVw>?	MYjJR\|UxRTFibl2=	MVGyN\|g1PDB\|OB?=
SK-MEL-1	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7oNVAh\|ryP	MW[3NkBp	MofRSG1UVw>?	MYPJR\|UxRTJibl2=	M1;EOlI{QDR2MEO4
M14	M3:1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4T0d\|ExKM7:TR?=	Mo\PO\|IhcA>?	NX7VfXRHTE2VTx?=	M2W1SGlEPTB;MjDuUS=>	MkmwNlM5PDRyM{i=
SK-MEL-28	M1q1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHMWHIyOCEQvF2=	NVvxfmtrPzJiaB?=	NF3RT4lFVVOR	MVzJR\|UxRTNibl2=	M17IeVI{QDR2MEO4
A375	M2HZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr4fmMyOCEQvF2=	MWG3NkBp	MWnEUXNQ	NXjv[II6UUN3ME20JI5O	NWDHOZRzOjN6NESwN\|g>
DU-4475	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOxNEDPxE1?	NYT4cmRwPzJiaB?=	NGK3VJVFVVOR	M{\2[mlEPTB;NTDuUS=>	NGK5PGEzOzh2NECzPC=>
UACC-257	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjxUXcyOTBizszN	NXr2OpJCPzJiaB?=	MUPEUXNQ	M1q0N2lEPTB;NjDuUS=>	NWfvSYcxOjN6NESwN\|g>
Colo 205	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDVN2wyOCEQvF2=	MkTGO\|IhcA>?	MU\EUXNQ	NHntV4xKSzVyPUegcm0>	MnvLNlM5PDRyM{i=
SK-MEL-3	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjYV3AyOTBizszN	NUj4T4x3PzJiaB?=	NXHaVpJNTE2VTx?=	M3nJZWlEPTB;NzDuUS=>	MXOyN\|g1PDB\|OB?=
SH-4	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVGxNEDPxE1?	Mn3GO\|IhcA>?	MlzkSG1UVw>?	MVrJR\|UxRThibl2=	NV;KO2M{OjN6NESwN\|g>
A101D	NX\uWJNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH3[VYyOCEQvF2=	NUm0bWFyPzJiaB?=	MmfqSG1UVw>?	MlK4TWM2OD17IH7N	MUSyN\|g1PDB\|OB?=
ES-2	M3rpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LMZlExKM7:TR?=	MkTYO\|IhcA>?	MV\EUXNQ	M{\mTmlEPTB;NUOgcm0>	NVmyS5JuOjN6NESwN\|g>
HT-29	M1vTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXtRocyOCEQvF2=	NEf5bpk4OiCq	MkHmSG1UVw>?	MkLrTWM2OD14NjDuUS=>	NUDKVFVrOjN6NESwN\|g>
SW1417	MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\GNVAh\|ryP	NHGxO244OiCq	NITrfpVFVVOR	NGjFcHhKSzVyPUG1PEBvVQ>?	NXLSdGN6OjN6NESwN\|g>
SW872	NFrHenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jlfFExKM7:TR?=	NHfGN\|I4OiCq	MUHEUXNQ	MVvJR\|UxRTN5NzDuUS=>	MmTwNlM5PDRyM{i=
RKO	MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;vNVAh\|ryP	NI\ocHk4OiCq	NUHMUIdGTE2VTx?=	MUjJR\|UxRTJwNUKyJO69VQ>?	NUnH[\|hjOjN6NESwN\|g>
A673	NHjNWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHGyNnUyOCEQvF2=	NX;Md5JuPzJiaB?=	NFK5bpFFVVOR	NFfubItKSzVyPUGwJO69VQ>?	NEftXFMzOzh2NECzPC=>
GCT	M33DTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3VOJlOOTBizszN	M{Hh[\|czKGh?	NI\iPZBFVVOR	Mn34TWM2OD1zMDFOwG0>	MWOyN\|g1PDB\|OB?=
WM-115	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYmxNEDPxE1?	NUDoVm9SPzJiaB?=	MnLHSG1UVw>?	NHPEeGlKSzVyPUWgcm0>	MWWyN\|g1PDB\|OB?=
YUMAC	NFrEZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4X4bFExKM7:TR?=	MU[3NkBp	MX;EUXNQ	MlraTWM2OD13IH7N	MlzNNlM5PDRyM{i=
OV-90	M3HxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\LWYEyOCEQvF2=	NWD4dG54PzJiaB?=	NYDwS2QzTE2VTx?=	NHnQRo1KSzVyPUK5JI5O	MUeyN\|g1PDB\|OB?=
NCI-H508	MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHKNVAh\|ryP	M3XIUVczKGh?	MV\EUXNQ	M2LHTmlEPTB;MUCg{txO	MW[yN\|g1PDB\|OB?=
MDA-MB-231	MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWe3WoxzOTBizszN	NEew[Ys4OiCq	NYXCfIs6TE2VTx?=	M3fpXWlEPTB;MUCg{txO	MnvPNlM5PDRyM{i=
SW756	M2nBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYD0c5Z4OTBizszN	NEXte3Y4OiCq	NGqzVI5FVVOR	NV;qdndGUUN3ME2xNEDPxE1?	M{O0clI{QDR2MEO4
SW-837	MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M334cVExKM7:TR?=	NWLobYVkPzJiaB?=	NXvoNlNUTE2VTx?=	MYXJR\|UxRTFyIN88US=>	NXHJdHJiOjN6NESwN\|g>
UMUC-3	NXr4WVluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PodFExKM7:TR?=	MV63NkBp	MX\EUXNQ	M4rqOGlEPTB;MUCg{txO	M1fMbVI{QDR2MEO4
LS-174T	NEDYXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYCxNEDPxE1?	MnLpO\|IhcA>?	NH7lZ5lFVVOR	M{nYNGlEPTB;MUCg{txO	M4iyfFI{QDR2MEO4
A549	M4XsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\lNVAh\|ryP	MWm3NkBp	NHj6OWZFVVOR	M4n6SWlEPTB;MUCg{txO	NF\IcHEzOzh2NECzPC=>
SHP-77	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M321dlExKM7:TR?=	MknzO\|IhcA>?	M{f4fGROW09?	NFPsdGVKSzVyPUGwJO69VQ>?	MUiyN\|g1PDB\|OB?=
SW480	NWr4cWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXixNEDPxE1?	MkLyO\|IhcA>?	M1XnPWROW09?	NETnV5VKSzVyPUGwJO69VQ>?	Mn7FNlM5PDRyM{i=
DLD-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\FVVExKM7:TR?=	MmG4O\|IhcA>?	MnnjSG1UVw>?	M3y2[2lEPTB;MUCg{txO	NUXIXGw3OjN6NESwN\|g>
HCT-116	M2DiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXQfGhVOTBizszN	MUG3NkBp	NWXROZRoTE2VTx?=	NI\tXXNKSzVyPUGwJO69VQ>?	M2O4bFI{QDR2MEO4
NCI-H747	M2O1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHGUlYxOTBizszN	Mlz0O\|IhcA>?	MV\EUXNQ	M4PXbmlEPTB;MUCg{txO	MlTlNlM5PDRyM{i=
T-84	M2LXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjsOoVPOTBizszN	MYm3NkBp	Ml\1SG1UVw>?	MljETWM2OD1zMDFOwG0>	NGf5SoczOzh2NECzPC=>
NCI-H460	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVX5SlBlOTBizszN	MUm3NkBp	MXvEUXNQ	M1XVbGlEPTB;MUCg{txO	M1PPNVI{QDR2MEO4
Calu-6	M2TaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;YNVAh\|ryP	NHzYZ2w4OiCq	NXHxN3d3TE2VTx?=	M2WxdWlEPTB;MUCg{txO	M37zZlI{QDR2MEO4
HCC-2998	MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTHcYsyOCEQvF2=	M4rjdFczKGh?	Ml7lSG1UVw>?	MnywTWM2OD1zMDFOwG0>	Ml[wNlM5PDRyM{i=
LS1034	NYfxRlZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojWNVAh\|ryP	NEG4WI04OiCq	NIH0PZRFVVOR	NUK4VWxQUUN3ME2xNEDPxE1?	MUeyN\|g1PDB\|OB?=
CHP-212	M3XJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGiySWEyOCEQvF2=	NIj3RW84OiCq	NY\wSpJ4TE2VTx?=	MYnJR\|UxRTFyIN88US=>	NFfOSZkzOzh2NECzPC=>
SK-N-AS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT3b\|F1OTBizszN	MYG3NkBp	MnnwSG1UVw>?	M1G5PGlEPTB;MUCg{txO	M{DXVlI{QDR2MEO4
BFTC-905	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PQ[FExKM7:TR?=	MYe3NkBp	MlnmSG1UVw>?	MnzpTWM2OD1zMDFOwG0>	NUTy[2tZOjN6NESwN\|g>
HuT78	NW\CbZExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYWzSZNiOTBizszN	MV23NkBp	NIG4e3dFVVOR	NH2wRXVKSzVyPUWyJI5O	MVyyN\|g1PDB\|OB?=
RPMI-8226	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK4fnNLOTBizszN	MXi3NkBp	MYjEUXNQ	MULJR\|UxRTJ4MzDuUS=>	MV6yN\|g1PDB\|OB?=
BC-3	M{\BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[4VnEyOCEQvF2=	NULwWoJPPzJiaB?=	NXHJOIVLTE2VTx?=	NF[wS\|JKSzVyPUK3O{BvVQ>?	M{SwSFI{QDR2MEO4
ACHN	NWrBZYJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvhN3MyOCEQvF2=	NGq4b284OiCq	NEno[IRFVVOR	MV;JR\|UxRTJ7NDDuUS=>	NIj1cWMzOzh2NECzPC=>
JRT3-T35	NFW4cmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDyd3EyOCEQvF2=	M2K0TlczKGh?	NEnnc5pFVVOR	MWDJR\|UxRTJ7NTDuUS=>	NHTjOXQzOzh2NECzPC=>
SK-MES-1	M{Xr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfuPVhJOTBizszN	Mlj0O\|IhcA>?	MojsSG1UVw>?	MonLTWM2OD1\|Mkmgcm0>	M1rVeVI{QDR2MEO4
CESS	M{HvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIGxPVcyOCEQvF2=	MkjPO\|IhcA>?	MWXEUXNQ	NEHi[2dKSzVyPUS5O{BvVQ>?	M2jIbVI{QDR2MEO4
H4	NHXnOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CyNlExKM7:TR?=	MYC3NkBp	NF2zSnBFVVOR	NYS0N2hKUUN3ME22NVkhdk1?	NVXmeJM4OjN6NESwN\|g>
BC-1	M3Psdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfROpoyOCEQvF2=	MUO3NkBp	MYXEUXNQ	M3vEZWlEPTB;N{C0JI5O	MVGyN\|g1PDB\|OB?=
DB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjyTpkyOCEQvF2=	M{Tuc\|czKGh?	MknOSG1UVw>?	MlH0TWM2OD16N{Ogcm0>	NVPuUZhDOjN6NESwN\|g>
RPMI-6666	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjWeIQyOCEQvF2=	NVzkd2JRPzJiaB?=	Mnv2SG1UVw>?	MU\JR\|UxRTl{ODDuUS=>	M1vtPVI{QDR2MEO4
MC/CAR	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLCO4IyOCEQvF2=	MUS3NkBp	M2DHPWROW09?	NI[1fVdKSzVyPUGuNFAzKM7:TR?=	NVu0bndoOjN6NESwN\|g>
SNU-1	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrSd4dDOTBizszN	MX63NkBp	NYXu[GZyTE2VTx?=	M{X1dGlEPTB;MT61NFEh\|ryP	MmjsNlM5PDRyM{i=
CEM/C1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXq4dGQ6OTBizszN	M4Dhb\|czKGh?	M3fDUWROW09?	NWm5cFR3UUN3ME2xMlc4OyEQvF2=	NWLjXHhoOjN6NESwN\|g>
GDM-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zUWVExKM7:TR?=	M2\NNFczKGh?	MXzEUXNQ	MVTJR\|UxRTFwOUm3JO69VQ>?	MYmyN\|g1PDB\|OB?=
HT-1080	NUnqUnNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDFdoFIOTBizszN	NYXUOnNGPzJiaB?=	NWXLUWZQTE2VTx?=	NEG3W4JKSzVyPUKuNFA1KM7:TR?=	NInuNW0zOzh2NECzPC=>
HL-60	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzEZYRrOTBizszN	MlzQO\|IhcA>?	M2PtOmROW09?	NUG5XYVwUUN3ME2yMlE4QCEQvF2=	NIXZfWEzOzh2NECzPC=>
C3A	NFzid25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn5UZoyOCEQvF2=	MnXsO\|IhcA>?	Mn34SG1UVw>?	NHfjd2VKSzVyPUWuOFE1KM7:TR?=	NF;4bXczOzh2NECzPC=>
MES-SA	NFvVbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXSxNEDPxE1?	MoPrO\|IhcA>?	MmHDSG1UVw>?	MWnJR\|UxRTZwOUi5JO69VQ>?	NGTD[HQzOzh2NECzPC=>
22Rv1	NH7jS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6xNEDPxE1?	M1vLclczKGh?	M1HvNmROW09?	NXjvZmt[UUN3ME2xNEDPxE1?	MV:yN\|g1PDB\|OB?=
647-V	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmxNEDPxE1?	NYf6doV2PzJiaB?=	NFnpclRFVVOR	MmDRTWM2OD1zMDFOwG0>	MXSyN\|g1PDB\|OB?=
786-O	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfSNVAh\|ryP	NWnVN\|BKPzJiaB?=	NGLLN21FVVOR	MojPTWM2OD1zMDFOwG0>	M4LvVlI{QDR2MEO4
A172	NWTnR5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DuPFExKM7:TR?=	NWL2VZQxPzJiaB?=	NXLj[40yTE2VTx?=	M3n5e2lEPTB;MUCg{txO	MXiyN\|g1PDB\|OB?=
A204	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P1V\|ExKM7:TR?=	MWG3NkBp	NGfBWmpFVVOR	NXfhOWVSUUN3ME2xNEDPxE1?	NXv0U5NpOjN6NESwN\|g>
A427	NGDleJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlv4NVAh\|ryP	NYrzVGpxPzJiaB?=	MV\EUXNQ	NXfVfZVUUUN3ME2xNEDPxE1?	MUSyN\|g1PDB\|OB?=
A431	M3;WeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zobFExKM7:TR?=	NW[wU\|hGPzJiaB?=	NIDDdJlFVVOR	NVfHSI5[UUN3ME2xNEDPxE1?	M1TTVlI{QDR2MEO4
A2780	M4DQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\yNVAh\|ryP	NWntcW96PzJiaB?=	M4rBd2ROW09?	MU\JR\|UxRTFyIN88US=>	NE[4c2ozOzh2NECzPC=>
ARH-77	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvj[m0yOCEQvF2=	MYW3NkBp	NVXMR5pUTE2VTx?=	M1fDcmlEPTB;MUCg{txO	M1;TOlI{QDR2MEO4
Be(2)C	M171TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLkNVAh\|ryP	M4rrfVczKGh?	M3zCXWROW09?	NITme4VKSzVyPUGwJO69VQ>?	NULSXZpLOjN6NESwN\|g>
BT-20	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWq4W3FLOTBizszN	MoPiO\|IhcA>?	NFvLU2FFVVOR	MnnxTWM2OD1zMDFOwG0>	NVzoeol7OjN6NESwN\|g>
BxPc3	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYThZ5ZiOTBizszN	NEfBXZg4OiCq	NVLpZ3JpTE2VTx?=	MYTJR\|UxRTFyIN88US=>	MkHyNlM5PDRyM{i=
C-4 I	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonlNVAh\|ryP	NEXMUIU4OiCq	M{XzeGROW09?	M1WyV2lEPTB;MUCg{txO	MlrTNlM5PDRyM{i=
C33A	NF3zWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M135PVExKM7:TR?=	NHvUNY44OiCq	MYnEUXNQ	M1u4RmlEPTB;MUCg{txO	M13vUlI{QDR2MEO4
CAL-27	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT6TFJWOTBizszN	NHqyc3Y4OiCq	M1jBOmROW09?	M2fSOGlEPTB;MUCg{txO	M4HzNVI{QDR2MEO4
CAL-62	Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDpSHhJOTBizszN	MVK3NkBp	MWjEUXNQ	MWTJR\|UxRTFyIN88US=>	NELkZZMzOzh2NECzPC=>
Calu-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVexNEDPxE1?	NITTT5I4OiCq	NFXVVGdFVVOR	NVLGVWFFUUN3ME2xNEDPxE1?	NUOxeYpMOjN6NESwN\|g>
CaOV3	NXf0Uph7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnDclcyOTBizszN	M1\lZVczKGh?	M4W3fGROW09?	MoLVTWM2OD1zMDFOwG0>	NWG1bYtvOjN6NESwN\|g>
CGTHW1	NUPibGw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqxNEDPxE1?	Mli1O\|IhcA>?	MX\EUXNQ	MnH6TWM2OD1zMDFOwG0>	M3jXVlI{QDR2MEO4
CHL-1	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHu1OFAyOCEQvF2=	NEm2e\|A4OiCq	MUjEUXNQ	MVTJR\|UxRTFyIN88US=>	MXiyN\|g1PDB\|OB?=
Colo320DM	NFnKPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHZW4lMOTBizszN	MYW3NkBp	Mn\1SG1UVw>?	MkSxTWM2OD1zMDFOwG0>	M4PpN\|I{QDR2MEO4
Colo704	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6xNEDPxE1?	M3LjTlczKGh?	NEjYenBFVVOR	M4\BU2lEPTB;MUCg{txO	M1rwOlI{QDR2MEO4
COR-L23	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzo[lEyOCEQvF2=	MUe3NkBp	MofOSG1UVw>?	MoLJTWM2OD1zMDFOwG0>	MlzMNlM5PDRyM{i=
CRO-AP2	NHT1eYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnYNVAh\|ryP	NUC2OZpLPzJiaB?=	NGnJV\|dFVVOR	MUDJR\|UxRTFyIN88US=>	M4nw[lI{QDR2MEO4
Daudi	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrzR5J1OTBizszN	MoThO\|IhcA>?	MXTEUXNQ	MXnJR\|UxRTFyIN88US=>	NHnYUFczOzh2NECzPC=>
DOTC 24510	M{f6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7SSm5TOTBizszN	MWC3NkBp	NVLIRndlTE2VTx?=	MVfJR\|UxRTFyIN88US=>	MX2yN\|g1PDB\|OB?=
DU-145	M2f6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W2blExKM7:TR?=	NULBWIt1PzJiaB?=	NWX4bGd1TE2VTx?=	MnK4TWM2OD1zMDFOwG0>	MV[yN\|g1PDB\|OB?=
EB-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHDWnFOOTBizszN	M13melczKGh?	MULEUXNQ	NIm1b25KSzVyPUGwJO69VQ>?	NWLwWIJDOjN6NESwN\|g>
EFM-19	NVm1XWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:xNEDPxE1?	NVX4WXU{PzJiaB?=	MUXEUXNQ	MoOwTWM2OD1zMDFOwG0>	NF\PO5ozOzh2NECzPC=>
EKVX	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHYZY4yOCEQvF2=	NIPoe2o4OiCq	M2exXWROW09?	NVzjVXMzUUN3ME2xNEDPxE1?	MnHpNlM5PDRyM{i=
FaDu	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnXNVAh\|ryP	MVy3NkBp	MUHEUXNQ	NUDtT414UUN3ME2xNEDPxE1?	MmPhNlM5PDRyM{i=
G401	M{n2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;QbVExKM7:TR?=	Mo[3O\|IhcA>?	NW\MeXdRTE2VTx?=	NYPw[WpLUUN3ME2xNEDPxE1?	MmHwNlM5PDRyM{i=
HCC-70	NUHxcFRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HGbFExKM7:TR?=	NWnaRYppPzJiaB?=	M33oUWROW09?	NYO0UW9YUUN3ME2xNEDPxE1?	MXyyN\|g1PDB\|OB?=
HCC-1954	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoP2NVAh\|ryP	M4KwbFczKGh?	NGPI[HZFVVOR	M37zV2lEPTB;MUCg{txO	MnHwNlM5PDRyM{i=
Hela	NFG0NFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHwNVAh\|ryP	MkXnO\|IhcA>?	NES4cHRFVVOR	NGTzbZZKSzVyPUGwJO69VQ>?	NUPZcmI6OjN6NESwN\|g>
Hep3B	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELZRWUyOCEQvF2=	MmG5O\|IhcA>?	NEDjco9FVVOR	MmroTWM2OD1zMDFOwG0>	NXjxcWZiOjN6NESwN\|g>
HMCB	NIXjcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	MUS3NkBp	MV;EUXNQ	MmGwTWM2OD1zMDFOwG0>	NIPCOY4zOzh2NECzPC=>
HN5	M1f6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfLTXcyOCEQvF2=	NVnrcmhoPzJiaB?=	NWn5VHdOTE2VTx?=	NGfx[WZKSzVyPUGwJO69VQ>?	MojPNlM5PDRyM{i=
HOS	MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rub\|ExKM7:TR?=	NIDwXJM4OiCq	NUfYZ2QxTE2VTx?=	NEnxO2ZKSzVyPUGwJO69VQ>?	MWeyN\|g1PDB\|OB?=
HPAF-II	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxNEDPxE1?	Mme2O\|IhcA>?	MUjEUXNQ	MXjJR\|UxRTFyIN88US=>	MoHQNlM5PDRyM{i=
Hs746.T	NWjp[pluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUKxNEDPxE1?	NILFPZo4OiCq	MWPEUXNQ	MmHOTWM2OD1zMDFOwG0>	NELMXYgzOzh2NECzPC=>
HT	NEPyW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTzbGZlOTBizszN	NULZV\|QyPzJiaB?=	NFXZXYtFVVOR	NFj4cGpKSzVyPUGwJO69VQ>?	MX[yN\|g1PDB\|OB?=
HT-3	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TJNlExKM7:TR?=	NXHTOWxzPzJiaB?=	MWfEUXNQ	MmH3TWM2OD1zMDFOwG0>	NF\2bGIzOzh2NECzPC=>
HuNS-1	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7tNVAh\|ryP	MWO3NkBp	NXPqdFV5TE2VTx?=	NWDjbnBiUUN3ME2xNEDPxE1?	MVyyN\|g1PDB\|OB?=
IGROV1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXUNVAh\|ryP	NHLsNIo4OiCq	NGW5S5pFVVOR	MXXJR\|UxRTFyIN88US=>	MVeyN\|g1PDB\|OB?=
J82	Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYWxNEDPxE1?	MoXxO\|IhcA>?	MXLEUXNQ	NYrjNmRmUUN3ME2xNEDPxE1?	NWjnWlFvOjN6NESwN\|g>
JM1	NEe5boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnn[poyOCEQvF2=	NXX3flBTPzJiaB?=	MmKzSG1UVw>?	MoTLTWM2OD1zMDFOwG0>	NF\SNm4zOzh2NECzPC=>
Kato III	Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYqxNEDPxE1?	NIOyVo04OiCq	MVnEUXNQ	Ml;LTWM2OD1zMDFOwG0>	NIjnXWozOzh2NECzPC=>
KHOS-240S	NYTZc5hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTNUlBPOTBizszN	NHniZ4g4OiCq	NULrS3gxTE2VTx?=	Mli5TWM2OD1zMDFOwG0>	NELx[nozOzh2NECzPC=>
KM-12	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPIPVE1OTBizszN	NFjOSJo4OiCq	NEnmXnJFVVOR	M4\VZmlEPTB;MUCg{txO	MVeyN\|g1PDB\|OB?=
KPL-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELtOXIyOCEQvF2=	MmjaO\|IhcA>?	MWPEUXNQ	NHz0cWtKSzVyPUGwJO69VQ>?	MlP3NlM5PDRyM{i=
KYSE-30	M3HXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjOe5NtOTBizszN	M1\mfFczKGh?	NX\pdHM5TE2VTx?=	NWXHToVtUUN3ME2xNEDPxE1?	M3:4OlI{QDR2MEO4
LNCaP	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLHT4QyOCEQvF2=	MYi3NkBp	M13nSGROW09?	M3i3cGlEPTB;MUCg{txO	NXvi[FNFOjN6NESwN\|g>
MCF-7	NXvwR5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYqxNEDPxE1?	MV63NkBp	MkXGSG1UVw>?	NGXCPVNKSzVyPUGwJO69VQ>?	MoDsNlM5PDRyM{i=
MC-IXC	M4SyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\HdVExKM7:TR?=	NH\tbZI4OiCq	MV;EUXNQ	MYDJR\|UxRTFyIN88US=>	NWjkXXA4OjN6NESwN\|g>
MDA-MB-175 VII	M1eyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7KNVAh\|ryP	NUG0ZXUyPzJiaB?=	Mke4SG1UVw>?	NWftbIxGUUN3ME2xNEDPxE1?	NWHid5VzOjN6NESwN\|g>
MDA-MB-468	NHTR[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PXN\|ExKM7:TR?=	M{PFTlczKGh?	M2XLbmROW09?	MX\JR\|UxRTFyIN88US=>	MlzuNlM5PDRyM{i=
MiaPaCa	Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPFNVAh\|ryP	NYjKVWVVPzJiaB?=	NIKzNVNFVVOR	NGXHWIZKSzVyPUGwJO69VQ>?	M1rYUlI{QDR2MEO4
Molt-4	NWnKVINsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\tV\|ExKM7:TR?=	M1HJVFczKGh?	NFjSbolFVVOR	MW\JR\|UxRTFyIN88US=>	NWjMXI46OjN6NESwN\|g>
NCI-ADR/RES	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{P6TVExKM7:TR?=	M2XYWlczKGh?	MXjEUXNQ	M3;mRWlEPTB;MUCg{txO	MVyyN\|g1PDB\|OB?=
NCI-H69	NXXBUI12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPPbIo3OTBizszN	MkHmO\|IhcA>?	NVO4cXF2TE2VTx?=	M2D3[WlEPTB;MUCg{txO	NHnGUFQzOzh2NECzPC=>
NCI-H82	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmr0NVAh\|ryP	M2DuU\|czKGh?	NIXXNoZFVVOR	MofhTWM2OD1zMDFOwG0>	NF3TcXUzOzh2NECzPC=>
NCI-N87	NFTtUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUSxNEDPxE1?	MojIO\|IhcA>?	NEDQSVhFVVOR	M3\NdmlEPTB;MUCg{txO	NXfjfYQxOjN6NESwN\|g>
NCI-H146	M4jMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETmRW0yOCEQvF2=	MUG3NkBp	NWjtTI9OTE2VTx?=	NHfsZmFKSzVyPUGwJO69VQ>?	MmXUNlM5PDRyM{i=
NCI-H157	Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\zNVAh\|ryP	MlziO\|IhcA>?	MofqSG1UVw>?	Mk\QTWM2OD1zMDFOwG0>	MkjxNlM5PDRyM{i=
NCI-H187	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TadVExKM7:TR?=	MoT1O\|IhcA>?	MWnEUXNQ	NV;j[FdNUUN3ME2xNEDPxE1?	NFPJRlkzOzh2NECzPC=>
NCI-H209	Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnPSos6OTBizszN	M{XIO\|czKGh?	NVjVXJdmTE2VTx?=	NITMPI5KSzVyPUGwJO69VQ>?	MoHuNlM5PDRyM{i=
NCI-H226	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTZNVAh\|ryP	MXq3NkBp	MlLTSG1UVw>?	M1\CbGlEPTB;MUCg{txO	NWC1fHJYOjN6NESwN\|g>
NCI-H292	M{HuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXr5WIp{OTBizszN	Mnv2O\|IhcA>?	MmT5SG1UVw>?	M{X6eWlEPTB;MUCg{txO	NYDJRmEyOjN6NESwN\|g>
NCI-H322	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q4PFExKM7:TR?=	M4nsdlczKGh?	NYHRO2R7TE2VTx?=	Ml2xTWM2OD1zMDFOwG0>	MnLVNlM5PDRyM{i=
NCI-H358	M{nYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXGNVAh\|ryP	MmKwO\|IhcA>?	M3ru[WROW09?	MmDyTWM2OD1zMDFOwG0>	MmTSNlM5PDRyM{i=
NCI-H520	M3j6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoKyNVAh\|ryP	NEXNR3Q4OiCq	NF7ZNm1FVVOR	M2n1VGlEPTB;MUCg{txO	NF7IeoIzOzh2NECzPC=>
NCI-H526	NF;RRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nzRlExKM7:TR?=	M2HpNFczKGh?	NUP4b2RRTE2VTx?=	MnXzTWM2OD1zMDFOwG0>	MXqyN\|g1PDB\|OB?=
NCI-H630	M1Tlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoOzNVAh\|ryP	NEn4WJM4OiCq	MnLMSG1UVw>?	MXTJR\|UxRTFyIN88US=>	MoPwNlM5PDRyM{i=
NCI-H661	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVL4U3QxOTBizszN	MU[3NkBp	Ml3jSG1UVw>?	NFG3clhKSzVyPUGwJO69VQ>?	MX6yN\|g1PDB\|OB?=
NCI-H716	NGfndVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPyNVAh\|ryP	M{XOXlczKGh?	Ml\USG1UVw>?	M3LLTGlEPTB;MUCg{txO	NYHRUlZvOjN6NESwN\|g>
NCI-H1563	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj3dlYyOCEQvF2=	Mlj6O\|IhcA>?	MUPEUXNQ	NYXTPWpoUUN3ME2xNEDPxE1?	NXnxfnpsOjN6NESwN\|g>
NCI-H1792	NUewPJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;FSVUyOCEQvF2=	MUS3NkBp	MmjISG1UVw>?	NFuwXWhKSzVyPUGwJO69VQ>?	NY\RS4dMOjN6NESwN\|g>
NCI-H2030	MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoG1NVAh\|ryP	NWGxd3lQPzJiaB?=	M1HxNWROW09?	NWnxNldvUUN3ME2xNEDPxE1?	MmHwNlM5PDRyM{i=
NCI-H2052	NV[4bHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[xNEDPxE1?	NEnQSVg4OiCq	NWfDb4JjTE2VTx?=	M3Pie2lEPTB;MUCg{txO	MYeyN\|g1PDB\|OB?=
NCI-H2122	M3raSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3X3XFExKM7:TR?=	M3;hW\|czKGh?	NWjrU41[TE2VTx?=	NVWzcmRJUUN3ME2xNEDPxE1?	MlrFNlM5PDRyM{i=
NCI-H2228	MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;GRVExKM7:TR?=	Ml\iO\|IhcA>?	M{PCdWROW09?	MXrJR\|UxRTFyIN88US=>	NYX3RWQ3OjN6NESwN\|g>
OE-19	NE\0[\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHny[IMyOCEQvF2=	NGDYdIg4OiCq	MUnEUXNQ	NGjQSVJKSzVyPUGwJO69VQ>?	M{fKblI{QDR2MEO4
OE-21	NYXBTpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnp[m5EOTBizszN	MUW3NkBp	NXKyR2FpTE2VTx?=	NUXWNlVlUUN3ME2xNEDPxE1?	MWWyN\|g1PDB\|OB?=
OE-33	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVj5[lBpOTBizszN	MmrOO\|IhcA>?	M3fLVGROW09?	M4LKU2lEPTB;MUCg{txO	NUD4e49qOjN6NESwN\|g>
OVCAR-3	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTPe5hoOTBizszN	MX63NkBp	M4TQcGROW09?	MlHtTWM2OD1zMDFOwG0>	MlH6NlM5PDRyM{i=
OVCAR-4	NHTBbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnmUoYyOCEQvF2=	NH7HWJI4OiCq	MXnEUXNQ	NXzoZ3RUUUN3ME2xNEDPxE1?	MmfhNlM5PDRyM{i=
OVCAR-5	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHUVJUyOCEQvF2=	M3;pdFczKGh?	MlnCSG1UVw>?	MV3JR\|UxRTFyIN88US=>	NHHiUFQzOzh2NECzPC=>
P3HR-1	M4Htb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDjZW1WOTBizszN	MVq3NkBp	NEm1dIZFVVOR	NVX6e2hEUUN3ME2xNEDPxE1?	M3;0WVI{QDR2MEO4
PC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWxNEDPxE1?	MWi3NkBp	MV7EUXNQ	NICzRXJKSzVyPUGwJO69VQ>?	M1HEPFI{QDR2MEO4
Raji	NIHFZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHO[3QyOCEQvF2=	MWG3NkBp	MUfEUXNQ	M1\uUmlEPTB;MUCg{txO	M1HBXFI{QDR2MEO4
RD	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfmd5YyOCEQvF2=	MXi3NkBp	NYjkN45jTE2VTx?=	NWfRV49iUUN3ME2xNEDPxE1?	NXvk[5B3OjN6NESwN\|g>
RD-ES	NETGUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jlcVExKM7:TR?=	MlvGO\|IhcA>?	NWexcoMzTE2VTx?=	NYnUWIxKUUN3ME2xNEDPxE1?	MnrnNlM5PDRyM{i=
RL	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDIUlBZOTBizszN	MVS3NkBp	MnTISG1UVw>?	MVrJR\|UxRTFyIN88US=>	NVfYeoUzOjN6NESwN\|g>
SaOS2	M{DIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml2xNVAh\|ryP	NF3SW2U4OiCq	M2nuTmROW09?	NIHRV4tKSzVyPUGwJO69VQ>?	MVqyN\|g1PDB\|OB?=
SCC-9	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2T6UVExKM7:TR?=	MnG5O\|IhcA>?	M4\T[2ROW09?	NFLlOWRKSzVyPUGwJO69VQ>?	NHHaXWczOzh2NECzPC=>
SCC-12	NGrOUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\FNVAh\|ryP	NUi1VWtsPzJiaB?=	MUfEUXNQ	MWLJR\|UxRTFyIN88US=>	MoXxNlM5PDRyM{i=
SCC-13	NFPUSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7K[nV{OTBizszN	MnqxO\|IhcA>?	NVHVSlhMTE2VTx?=	MkXXTWM2OD1zMDFOwG0>	MXiyN\|g1PDB\|OB?=
SCC-15	NE\hNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPBUm1pOTBizszN	NFnR[W04OiCq	NGrFeGFFVVOR	M4nLe2lEPTB;MUCg{txO	MXiyN\|g1PDB\|OB?=
SCC-25	NFy4OmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULw[XhUOTBizszN	M3jWV\|czKGh?	Mom3SG1UVw>?	MX\JR\|UxRTFyIN88US=>	NXi1dFkxOjN6NESwN\|g>
SCLC-3	MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfwVGNrOTBizszN	NXfCOohOPzJiaB?=	Mn;QSG1UVw>?	MVnJR\|UxRTFyIN88US=>	NVjNWXcxOjN6NESwN\|g>
SF-268	NVeyeWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTFeIcyOCEQvF2=	NInoN244OiCq	NXjvOXQ4TE2VTx?=	MlLwTWM2OD1zMDFOwG0>	NYHrXW01OjN6NESwN\|g>
SF-295	NVzUXVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYOxNEDPxE1?	MlHaO\|IhcA>?	M4m2W2ROW09?	MV;JR\|UxRTFyIN88US=>	NHzMPYozOzh2NECzPC=>
SJRH30	NGXyOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYi5bldyOTBizszN	MV[3NkBp	NVLlbWJsTE2VTx?=	NX\ZSFB5UUN3ME2xNEDPxE1?	MlT4NlM5PDRyM{i=
SK-BR-3	M4mzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:xWm55OTBizszN	NHHvOXA4OiCq	MnTjSG1UVw>?	NYK5SGw4UUN3ME2xNEDPxE1?	MlfnNlM5PDRyM{i=
SK-LMS-1	M{ft[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmX2NVAh\|ryP	MV63NkBp	M2XjN2ROW09?	NGLGbnBKSzVyPUGwJO69VQ>?	MluyNlM5PDRyM{i=
SK-N-DZ	M1;nfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zDcFExKM7:TR?=	M1PQVFczKGh?	NVXCcWFxTE2VTx?=	M{fjV2lEPTB;MUCg{txO	MkHzNlM5PDRyM{i=
SK-N-F1	NU\rNZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHZNVAh\|ryP	MUe3NkBp	MVjEUXNQ	M{DmPWlEPTB;MUCg{txO	NWX3fnFLOjN6NESwN\|g>
SKOV-3	NGLoVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEC0WHcyOCEQvF2=	MX23NkBp	MX;EUXNQ	M2PoR2lEPTB;MUCg{txO	MmrONlM5PDRyM{i=
SK-UT-1	NIf2RolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jNdFExKM7:TR?=	M1[xbFczKGh?	M{LHO2ROW09?	MoXpTWM2OD1zMDFOwG0>	MX[yN\|g1PDB\|OB?=
SN12C	NF7UbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mli0NVAh\|ryP	MVi3NkBp	M{jMZmROW09?	MVnJR\|UxRTFyIN88US=>	MV[yN\|g1PDB\|OB?=
SNB-19	M3foTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnNSZZMOTBizszN	M{[0OFczKGh?	M1uz[WROW09?	M4XUNWlEPTB;MUCg{txO	NG\p[FIzOzh2NECzPC=>
SNU-5	M{HPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvKVGkyOCEQvF2=	MYK3NkBp	MYLEUXNQ	MnPBTWM2OD1zMDFOwG0>	Mn31NlM5PDRyM{i=
SNU-16	M2mzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHiNVAh\|ryP	MVu3NkBp	Ml;ZSG1UVw>?	M4GzUGlEPTB;MUCg{txO	M4nGe\|I{QDR2MEO4
SNU-398	M{PGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPZNVAh\|ryP	M2n5[VczKGh?	NXLLT3FUTE2VTx?=	Ml36TWM2OD1zMDFOwG0>	M37YTFI{QDR2MEO4
SNU-449	NUj2U4FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYC5dGM{OTBizszN	NUWxOll1PzJiaB?=	MWnEUXNQ	NUDIWlVoUUN3ME2xNEDPxE1?	NIrtNW0zOzh2NECzPC=>
SR	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmSxNVAh\|ryP	MlTUO\|IhcA>?	MnLaSG1UVw>?	M4HjSmlEPTB;MUCg{txO	MojJNlM5PDRyM{i=
ST486	M4Pi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrObVhtOTBizszN	MnfJO\|IhcA>?	NH[5cm9FVVOR	NXTCTG5uUUN3ME2xNEDPxE1?	NHTJO4kzOzh2NECzPC=>
SW579	M3rwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7PdlIyOCEQvF2=	MWi3NkBp	NGPCbJZFVVOR	M1XGXWlEPTB;MUCg{txO	M{n0cVI{QDR2MEO4
SW684	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvWNVAh\|ryP	MoPkO\|IhcA>?	NIDMZ4ZFVVOR	M3iw[2lEPTB;MUCg{txO	NEDyeowzOzh2NECzPC=>
SW-780	NEHGb\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vUWFExKM7:TR?=	M2DkW\|czKGh?	MV;EUXNQ	MkC4TWM2OD1zMDFOwG0>	NVrOW3FqOjN6NESwN\|g>
SW900	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nZO\|ExKM7:TR?=	M2joOFczKGh?	MYLEUXNQ	Mkj1TWM2OD1zMDFOwG0>	M1jhbFI{QDR2MEO4
SW1088	NUTuTJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2D3VVExKM7:TR?=	MnrwO\|IhcA>?	NYraepI3TE2VTx?=	MnfWTWM2OD1zMDFOwG0>	NXjYXI5IOjN6NESwN\|g>
SW1463	NYHpN2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nKVVExKM7:TR?=	NHHCWYo4OiCq	NY\OPWVGTE2VTx?=	MYnJR\|UxRTFyIN88US=>	MkTPNlM5PDRyM{i=
SW1990	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\vd2MyOCEQvF2=	M1;PbFczKGh?	NW\LZXpFTE2VTx?=	MV7JR\|UxRTFyIN88US=>	NWf4e2VTOjN6NESwN\|g>
T47D	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH76RpoyOCEQvF2=	NWrSU3pbPzJiaB?=	NFzYcWVFVVOR	M{LVdmlEPTB;MUCg{txO	NYHPNpRrOjN6NESwN\|g>
TE381.T	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFz0VVgyOCEQvF2=	MmiyO\|IhcA>?	MkL1SG1UVw>?	Mn7XTWM2OD1zMDFOwG0>	NE\rRmczOzh2NECzPC=>
TK-10	NVXYWplST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWGxNEDPxE1?	NEXqcGw4OiCq	NXK1T\|NyTE2VTx?=	NHXvPGpKSzVyPUGwJO69VQ>?	M1rTVFI{QDR2MEO4
U2OS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HOXFExKM7:TR?=	M3HON\|czKGh?	M4LP[GROW09?	MUTJR\|UxRTFyIN88US=>	MYCyN\|g1PDB\|OB?=
U251	MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfV[W4yOCEQvF2=	NWjBeFRNPzJiaB?=	MoHsSG1UVw>?	NWfTcnREUUN3ME2xNEDPxE1?	NYS3XpliOjN6NESwN\|g>
UACC-812	NH;UeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYixNEDPxE1?	NF3LOlc4OiCq	NFXKPWNFVVOR	MVrJR\|UxRTFyIN88US=>	NYfEcWp5OjN6NESwN\|g>
YAPC	MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVyxNEDPxE1?	MknMO\|IhcA>?	MWnEUXNQ	NHvsWVZKSzVyPUGwJO69VQ>?	M1fteFI{QDR2MEO4
ZR-75-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTzV28yOCEQvF2=	M1q0XlczKGh?	M4HYeWROW09?	NULhUpE6UUN3ME2xNEDPxE1?	MoHnNlM5PDRyM{i=
A375	M3PBfWZ2dmO2aX;uJIF{e2G7	MWOxMlIh\|ryP	NWi3emhvPCCq	NWHNNoloTE2VTx?=	NVj3RWZqUW6qaXLpeIlwdiCxZjDwbI9{eGixconsZZRqd25ib3[gUWVMNCCHUlusJIFv\CCVNmC=	Mk\vNlI{QDl2N{G=
YUSIT1	M3PjNWZ2dmO2aX;uJIF{e2G7			NUfZ[npLTE2VTx?=	MnTHdoVlfWOnZDDz[Y5{cXSrdnn0fUB4cXSqIFnDOVAhRiByLkWg{txO	MYqyNlM5QTR5MR?=
MeWo	NILKfGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MYHEUXNQ	MVPJR\|UxKD1iOUi3JI5O	NWC4OYpZOjZyMUi1NlQ>
WiDr	M3PTeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NEf1PHJFVVOR	NYrEbJJnUUN3MDC9JFc3KG6P	NVfG[II{OjZyMUi1NlQ>
Colo-205	NX\6OVFvTnWwY4Tpc44h[XO\|YYm=	NVf0b5lZOSEQvF2=	MmTvOEBl	NVTFcYlWTE2VTx?=	MofCTY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm	NH3O[3UzPTN6MUG1Ni=>
RBW-1	NUS0NVRRTnWwY4Tpc44h[XO\|YYm=	NEfXWYMyKM7:TR?=		MmC0SG1UVw>?	MWjOc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	M1PMSVI1QDh3Nkmw
RBO-1	NUnJUm9zTnWwY4Tpc44h[XO\|YYm=	M4\PRlEh\|ryP		NILrdIhFVVOR	NFXyV4NKdmirYnn0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v	NHnzOVUzPDh6NU[5NC=>
RBO-2	NGXxN\|lHfW6ldHnvckBie3OjeR?=	NELyNoUyKM7:TR?=		NUG2R4lZTE2VTx?=	MkPlTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	MkjENlQ5QDV4OUC=
RBOW	MWrGeY5kfGmxbjDhd5NigQ>?	NXGzeGZIOSEQvF2=		MkH2SG1UVw>?	MWDJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	MmjkNlQ5QDV4OUC=
M257	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jBPFExOCCwTR?=	M{DlNVczKGh?		M2jvV2Rw\XNibn;0JIlvcGmkaYSgdJJwdGmoZYLheIlwdiCxZjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?=	NHXKb\|gzOzNzN{S0Oi=>
LCP	M3fRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnFS4wyODBibl2=	NFLaWXI4OiCq		NFWwUXFKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZiTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v	Ml20NlM{OTd2NE[=
WM266	M{LWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX6xNFAhdk1?	NV\TeWZPPzJiaB?=		NVf0fGVkUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFFFKG23dHHueIF1cW:w	M4n3[\|I{OzF5NES2
M257	NF7FSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7yNVAxKG6P	MmPDO\|IhcA>?		NGfUTFlFd2W\|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	M1jEbVI{OzF5NES2
LCP	M{nuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIj4WXEyODBibl2=	MnPoO\|IhcA>?		MmTNTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	MW[yN\|MyPzR2Nh?=
WM266	M1;1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTadZEyODBibl2=	MVW3NkBp		NFOxPW1KdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36=	NVfXbGNpOjN\|MUe0OFY>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(F)C(=CC=C3)N[S](=O)(=O)C4=C(F)C=CC=C4F

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2
NCT03668431	Recruiting	Drug: Dabrafenib\|Drug: Trametinib\|Drug: PDR001	Metastatic Colorectal Cancer	Massachusetts General Hospital\|Novartis\|Stand Up To Cancer	October 15 2018	Phase 2
NCT03553329	Completed	Drug: dabrafenib	Unresecable Stage IIIc or IV Melanoma	Poitiers University Hospital	June 2 2018	--
NCT03593993	Recruiting	Procedure: Surgical Cohort	Glioma\|BRAF V600E\|Pleomorphic Xantho-Astrocytoma\|Glioblastoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Musella Foundation	May 19 2018	--
NCT03340506	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma\|Non Small Cell Lung Cancer\|Solid Tumor\|Rare Cancers\|High Grade Glioma	Novartis Pharmaceuticals\|Novartis	December 28 2017	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)